Van­da buys J&J's mul­ti­ple scle­ro­sis drug Pon­vory for $100M

Van­da Phar­ma­ceu­ti­cals has paid $100 mil­lion to Acte­lion Phar­ma­ceu­ti­cals, a John­son & John­son com­pa­ny, for the US and Cana­da rights to mul­ti­ple scle­ro­sis drug Pon­vory.

The drug, an oral se­lec­tive sphin­go­sine-1-phos­phate re­cep­tor 1 (S1P1R) mod­u­la­tor, was ap­proved in 2021 for adults with re­laps­ing forms of mul­ti­ple scle­ro­sis af­ter show­ing su­pe­ri­or ef­fi­ca­cy to stan­dard of care Auba­gio (ter­i­fluno­mide).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER